KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Investing Activities: 2011-2025

Historic Cash from Investing Activities for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to -$10.0 million.

  • Arbutus Biopharma's Cash from Investing Activities rose 16.41% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year decrease of 4.44%. This contributed to the annual value of $22.9 million for FY2024, which is 54.80% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Cash from Investing Activities of -$10.0 million as of Q3 2025, which was down 164.18% from $15.6 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Cash from Investing Activities peaked at $22.2 million during Q4 2023, and registered a low of -$60.1 million during Q1 2022.
  • For the 3-year period, Arbutus Biopharma's Cash from Investing Activities averaged around $8.2 million, with its median value being $11.3 million (2025).
  • In the last 5 years, Arbutus Biopharma's Cash from Investing Activities skyrocketed by 858.89% in 2021 and then crashed by 429.60% in 2022.
  • Arbutus Biopharma's Cash from Investing Activities (Quarterly) stood at -$8.1 million in 2021, then soared by 256.16% to $12.7 million in 2022, then skyrocketed by 75.25% to $22.2 million in 2023, then tumbled by 39.66% to $13.4 million in 2024, then increased by 16.41% to -$10.0 million in 2025.
  • Its last three reported values are -$10.0 million in Q3 2025, $15.6 million for Q2 2025, and $11.3 million during Q1 2025.